| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
Recent advances in recurrent hepatocellular carcinoma therapy
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Yu-Xue Gao, Qi-Qi Ning, Peng-Xiang Yang, Yuan-Yue Guan, Peng-Xiang Liu, Meng-Lu Liu, Lu-Xin Qiao, Xiang-Hua Guo, Tong-Wang Yang and De-Xi Chen |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China |
82073676 |
| Chinesisch-Deutsches Forschungsprojekt in Sonderprogramm zu COVID-19 |
C-0012 |
| Key Programs of Beijing Municipal Education Commission of China |
KZ202010025037 |
| Third Round of Public Welfare Development and Reform Pilot Projects of Beijing Municipal Medical Research Institutes |
Jing 2019-6 |
| Fourth Round of Public Welfare Development and Reform Pilot Projects of Beijing Municipal Medical Research Institutes |
Jing 2021-10 |
|
| Corresponding Author |
De-Xi Chen, PhD, Professor, Beijing Institute of Hepatology, Beijing You An Hospital, Capital Medical University, No. 8 Youanmenwai, Youanmen Street, Fengtai District, Beijing 100069, China. dexichen@ccmu.edu.cn |
| Key Words |
Recurrent hepatocellular carcinoma; Liver transplantation; Therapy; Immunotherapy; Neoadjuvant and adjuvant therapy |
| Core Tip |
Hepatocellular carcinoma (HCC) is the most prevalent form of primary liver cancer, and up to 50%-70% of individuals may experience a relapse of the illness in the liver after 5 years. This review will provide novel approaches to improve the prognosis of patients with recurring HCC with the apparent lack of data to guide the clinical treatment. Neoadjuvant and/or adjuvant therapy methods potentially elevate the opportunity of cure in refractory patients with recurrent HCC and contribute to a better long-term prognosis. |
| Publish Date |
2023-04-20 07:26 |
| Citation |
Gao YX, Ning QQ, Yang PX, Guan YY, Liu PX, Liu ML, Qiao LX, Guo XH, Yang TW, Chen DX. Recent advances in recurrent hepatocellular carcinoma therapy. World J Hepatol 2023; 15(4): 460-476 |
| URL |
https://www.wjgnet.com/1948-5182/full/v15/i4/460.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v15.i4.460 |
